Relmada Therapeutics Future Growth
Future criteria checks 0/6
Relmada Therapeutics is forecast to grow earnings and revenue by 12.5% and 32% per annum respectively while EPS is expected to grow by 30.8% per annum.
Key information
12.5%
Earnings growth rate
30.8%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 32.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 05 Dec 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 10 | -41 | -69 | N/A | 3 |
| 12/31/2025 | N/A | -47 | -65 | N/A | 3 |
| 12/31/2024 | N/A | -83 | -55 | N/A | 3 |
| 9/30/2024 | N/A | -86 | -53 | -53 | N/A |
| 6/30/2024 | N/A | -87 | -48 | -48 | N/A |
| 3/31/2024 | N/A | -94 | -48 | -48 | N/A |
| 12/31/2023 | N/A | -99 | -52 | -52 | N/A |
| 9/30/2023 | N/A | -112 | -77 | -77 | N/A |
| 6/30/2023 | N/A | -129 | -93 | -93 | N/A |
| 3/31/2023 | N/A | -144 | -101 | -101 | N/A |
| 12/31/2022 | N/A | -157 | -104 | -104 | N/A |
| 9/30/2022 | N/A | -153 | -106 | -106 | N/A |
| 6/30/2022 | N/A | -157 | -100 | -100 | N/A |
| 3/31/2022 | N/A | -143 | -95 | -95 | N/A |
| 12/31/2021 | N/A | -126 | -92 | -92 | N/A |
| 9/30/2021 | N/A | -112 | -61 | -61 | N/A |
| 6/30/2021 | N/A | -86 | -53 | -53 | N/A |
| 3/31/2021 | N/A | -71 | -40 | -40 | N/A |
| 12/31/2020 | N/A | -59 | -28 | -28 | N/A |
| 9/30/2020 | N/A | -43 | -25 | -25 | N/A |
| 6/30/2020 | N/A | -30 | -15 | -15 | N/A |
| 3/31/2020 | N/A | -23 | -14 | -14 | N/A |
| 12/31/2019 | N/A | -15 | -12 | -12 | N/A |
| 9/30/2019 | N/A | -18 | -11 | -11 | N/A |
| 6/30/2019 | N/A | -17 | -10 | -10 | N/A |
| 3/31/2019 | N/A | -17 | -9 | -9 | N/A |
| 12/31/2018 | N/A | -17 | -9 | -9 | N/A |
| 9/30/2018 | N/A | -11 | -7 | -7 | N/A |
| 6/30/2018 | N/A | -9 | N/A | -6 | N/A |
| 3/31/2018 | N/A | -7 | N/A | -5 | N/A |
| 12/31/2017 | N/A | -6 | N/A | -5 | N/A |
| 9/30/2017 | N/A | -6 | N/A | -5 | N/A |
| 6/30/2017 | N/A | -6 | N/A | -6 | N/A |
| 3/31/2017 | N/A | -8 | N/A | -8 | N/A |
| 12/31/2016 | N/A | -8 | N/A | -10 | N/A |
| 9/30/2016 | N/A | -9 | N/A | -12 | N/A |
| 6/30/2016 | N/A | -3 | N/A | -13 | N/A |
| 3/31/2016 | N/A | 6 | N/A | -15 | N/A |
| 12/31/2015 | N/A | 6 | N/A | -16 | N/A |
| 9/30/2015 | N/A | 14 | N/A | -17 | N/A |
| 6/30/2015 | N/A | -21 | N/A | -16 | N/A |
| 3/31/2015 | N/A | -55 | N/A | -13 | N/A |
| 12/31/2014 | N/A | -46 | N/A | -9 | N/A |
| 9/30/2014 | N/A | -56 | N/A | -5 | N/A |
| 6/30/2014 | N/A | -28 | N/A | -3 | N/A |
| 3/31/2014 | N/A | -13 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4E2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 4E2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 4E2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 4E2 is forecast to have no revenue next year.
High Growth Revenue: 4E2 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4E2's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 02:42 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Relmada Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Maxim Jacobs | Edison Investment Research |
| Yatin Suneja | Guggenheim Securities, LLC |